[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA33604B1 - Composés et compositions en tant qu'inhibiteurs de protéine kinase - Google Patents

Composés et compositions en tant qu'inhibiteurs de protéine kinase

Info

Publication number
MA33604B1
MA33604B1 MA34716A MA34716A MA33604B1 MA 33604 B1 MA33604 B1 MA 33604B1 MA 34716 A MA34716 A MA 34716A MA 34716 A MA34716 A MA 34716A MA 33604 B1 MA33604 B1 MA 33604B1
Authority
MA
Morocco
Prior art keywords
formulations
components
protein kinase
kinase inhibitors
compounds
Prior art date
Application number
MA34716A
Other languages
Arabic (ar)
English (en)
Inventor
Shenlin Huang
Xianming Jin
Zuosheng Liu
Daniel Poon
John E Tellew
Yongqin Wan
Xing Wang
Yongping Xie
Original Assignee
Novartis Ag
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42782253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33604(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Irm Llc filed Critical Novartis Ag
Publication of MA33604B1 publication Critical patent/MA33604B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention porte sur une nouvelle classe de composés de la formule 1, sur des compositions pharmaceutiques comportant de tels composés et sur des procédés d'utilisation de tels composés pour traiter ou prévenir des maladies ou des troubles associés à une activité kinase anormale ou dérégulée, en particulier des maladies ou des troubles qui entraînent une activation anormale de b-raf.
MA34716A 2009-08-28 2012-03-23 Composés et compositions en tant qu'inhibiteurs de protéine kinase MA33604B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23807309P 2009-08-28 2009-08-28
US31303910P 2010-03-11 2010-03-11
PCT/US2010/046930 WO2011025927A1 (fr) 2009-08-28 2010-08-27 Composés et compositions en tant qu'inhibiteurs de protéine kinase

Publications (1)

Publication Number Publication Date
MA33604B1 true MA33604B1 (fr) 2012-09-01

Family

ID=42782253

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34716A MA33604B1 (fr) 2009-08-28 2012-03-23 Composés et compositions en tant qu'inhibiteurs de protéine kinase

Country Status (50)

Country Link
US (12) US8501758B2 (fr)
EP (2) EP2470526B1 (fr)
JP (2) JP5475888B2 (fr)
KR (1) KR101413392B1 (fr)
CN (2) CN103896921B (fr)
AR (1) AR077975A1 (fr)
AU (1) AU2010286569C1 (fr)
BR (1) BR112012004453B1 (fr)
CA (1) CA2771775C (fr)
CL (1) CL2012000340A1 (fr)
CO (1) CO6612222A2 (fr)
CR (1) CR20120102A (fr)
CU (1) CU24110B1 (fr)
CY (3) CY1118452T1 (fr)
DK (2) DK2727918T3 (fr)
DO (1) DOP2012000051A (fr)
EA (2) EA201500175A1 (fr)
EC (2) ECSP12011700A (fr)
ES (2) ES2610825T3 (fr)
GE (1) GEP20146102B (fr)
GT (1) GT201200053A (fr)
HK (1) HK1167390A1 (fr)
HN (1) HN2012000441A (fr)
HR (2) HRP20140799T1 (fr)
HU (3) HUE032847T2 (fr)
IL (1) IL218084A (fr)
IN (1) IN2012DN02469A (fr)
JO (1) JO3002B1 (fr)
LT (3) LT2727918T (fr)
LU (2) LUC00101I2 (fr)
MA (1) MA33604B1 (fr)
ME (2) ME02684B (fr)
MX (1) MX2012002546A (fr)
MY (1) MY156259A (fr)
NI (1) NI201200029A (fr)
NL (1) NL300973I2 (fr)
NO (2) NO2019012I1 (fr)
NZ (1) NZ598924A (fr)
PE (1) PE20120861A1 (fr)
PL (2) PL2470526T3 (fr)
PT (2) PT2470526E (fr)
RS (2) RS53489B1 (fr)
SG (2) SG178351A1 (fr)
SI (2) SI2470526T1 (fr)
SM (2) SMT201400133B (fr)
TN (1) TN2012000081A1 (fr)
UA (1) UA112285C2 (fr)
UY (1) UY32860A (fr)
WO (1) WO2011025927A1 (fr)
ZA (1) ZA201202020B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CN103002894B (zh) 2010-02-25 2016-04-06 达纳－法伯癌症研究所公司 对braf抑制剂具有抗性的braf突变
US8907270B2 (en) 2010-06-30 2014-12-09 Schlumberger Technology Corporation Method and apparatus for gain regulation in a gamma detector
CA2855243C (fr) * 2011-11-11 2020-04-14 Novartis Ag Procede de traitement d'une maladie proliferative
JP6216325B2 (ja) 2011-11-23 2017-10-18 ノバルティス アーゲー 医薬製剤
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN103159736B (zh) * 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
JP2015503505A (ja) * 2011-12-23 2015-02-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヘテロアリールおよびその使用
EP3333575B1 (fr) 2012-03-28 2020-02-26 Dana Farber Cancer Institute, Inc. Mutants c-raf qui conférant resistance aux inhibiteurs de la raf
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
AU2013292580B2 (en) 2012-07-18 2017-07-20 Saint Louis University Beta amino acid derivatives as integrin antagonists
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
DK2882440T3 (da) 2012-08-07 2019-05-06 Novartis Ag Farmaceutiske kombinationer, der omfatter en b-raf-inhibitor, en egfr-inhibitor og eventuelt en pi3k-alfa-inhibitor
KR20240146112A (ko) 2012-08-17 2024-10-07 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
US20150232452A1 (en) * 2012-09-19 2015-08-20 Ruga Corporation Novel raf kinase inhibitors
RU2015121367A (ru) 2012-11-08 2017-01-10 Новартис Аг Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний
CN112641787A (zh) 2013-03-21 2021-04-13 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
TWI634114B (zh) * 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
EP3004060B1 (fr) * 2013-05-30 2019-11-27 Plexxikon Inc. Composés pour modulation de kinases, et indications correspondantes
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
EP3082800B1 (fr) * 2013-12-20 2022-02-02 Biomed Valley Discoveries, Inc. Traitement du cancer faisant appel à des associations d'inhibiteurs de l'erk et de la raf
RU2016129953A (ru) * 2013-12-23 2018-01-30 Новартис Аг Фармацевтические комбинации
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
DE102015103158A1 (de) 2014-03-04 2015-09-10 Bergische Universität Wuppertal Verbindungen für die Behandlung des Melanoms
UY36032A (es) 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
WO2015145388A2 (fr) 2014-03-27 2015-10-01 Novartis Ag Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt
WO2015175846A2 (fr) * 2014-05-16 2015-11-19 University Of Massachusetts Traitement de la leucémie myéloïde chronique (lmc)
WO2015196072A2 (fr) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Utilisations d'inhibiteurs de kinase pour l'induction et le maintien de la pluripotence
US10167279B2 (en) * 2014-09-12 2019-01-01 Novartis Ag Compounds and compositions as RAF kinase inhibitors
WO2016040892A1 (fr) 2014-09-13 2016-03-17 Novartis Ag Polythérapies
WO2016054555A2 (fr) 2014-10-03 2016-04-07 Novartis Ag Polythérapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
WO2017019897A1 (fr) 2015-07-29 2017-02-02 Novartis Ag Polythérapies comprenant des molécules d'anticorps contre tim -3
CN116059344A (zh) 2015-11-03 2023-05-05 詹森生物科技公司 特异性结合pd-1的抗体及其用途
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
CN108779077A (zh) 2015-12-30 2018-11-09 圣路易斯大学 作为pan整合素拮抗剂的间位氮杂环氨基苯甲酸衍生物
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
SG11201810793XA (en) 2016-06-03 2018-12-28 Giordano Caponigro Pharmaceutical combinations
EP3507367A4 (fr) 2016-07-05 2020-03-25 Aduro BioTech, Inc. Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
EP3564232B1 (fr) * 2016-12-27 2022-01-26 Riken Composé inhibiteur de signal bmp
WO2018146253A1 (fr) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour le traitement de cancers associés à l'activation de la voie mapk
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107540699A (zh) * 2017-10-16 2018-01-05 康化（上海）新药研发有限公司 一种2‑氨基‑3‑氟吡啶‑4‑硼酸盐酸盐的合成方法
CA3086765A1 (fr) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Systemes de culture de cellules souches pour cellules souches epitheliales colonnaires, et leurs utilisations
JP7262843B2 (ja) * 2018-07-12 2023-04-24 深▲チェン▼市塔吉瑞生物医薬有限公司 ジアリールピラゾール化合物、該化合物を含む組成物およびその使用
WO2020124397A1 (fr) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. Inhibiteurs de kinase src c-terminale
EP3903828A4 (fr) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de kinase
JP7234418B2 (ja) 2019-05-16 2023-03-07 イーライ リリー アンド カンパニー Ｂｒａｆｖ６００ｅ大腸癌の治療に使用するためのｅｒｋ１／２阻害剤と、ｂｒａｆ阻害剤およびｅｇｆｒ阻害剤との三重組み合わせ
KR20220131229A (ko) 2019-12-05 2022-09-27 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) N-(3-(5-(피리미딘-4-일)티아졸-4-일)페닐)설폰아미드 화합물 및 이의 용도
WO2022036176A1 (fr) 2020-08-13 2022-02-17 Albert Einstein College Of Medicine N-cyclyl-sulfonamides utiles pour inhiber raf
MX2023003867A (es) 2020-10-05 2023-04-18 Pf Medicament Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii.
JP2024511373A (ja) 2021-03-18 2024-03-13 ノバルティス アーゲー がんのためのバイオマーカーおよびその使用
IL307964A (en) 2021-06-09 2023-12-01 Chugai Pharmaceutical Co Ltd Combined treatment for cancer
CN114557977A (zh) * 2022-02-16 2022-05-31 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
WO2023230554A1 (fr) 2022-05-25 2023-11-30 Pfizer Inc. Combinaison d'un inhibiteur de braf, d'un inhibiteur d'egfr et d'un antagoniste de pd-1 pour le traitement du cancer colorectal msi-h/dmmr, avec mutation v600e de braf
WO2024163166A1 (fr) * 2023-01-30 2024-08-08 5Metis, Inc. Composés contenant du bore et leurs utilisations

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4104250A (en) * 1976-08-11 1978-08-01 Borg-Warner Corporation Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
EP0184384B1 (fr) 1984-12-06 1989-08-02 Pfizer Inc. Acides dihydroquinolonecarboxyliques substitués et compositions antibactériennes les contenant
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
WO1997008950A1 (fr) 1995-09-07 1997-03-13 Fuisz Technologies, Ltd. Systeme permettant de rendre biodisponibles des agents bioalterants sensiblement non solubles
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AU728701B2 (en) 1996-05-23 2001-01-18 Applied Research Systems Ars Holding N.V. Compounds that inhibit the binding of Raf-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
GEP20033053B (en) 1997-05-22 2003-08-25 Searle & Co Substituted Pyrazoles as P38 Kinase Inhibitors, Methods for their Production, Pharmaceutical Compositions Containing Them and Methods for Treatment
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
JP5159012B2 (ja) 1999-12-23 2013-03-06 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 不良溶解性の薬物に対する改良された医薬組成物
AU2001285349A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2464309C (fr) 2001-10-25 2012-01-03 Novartis Ag Combinaisons comprenant un inhibiteur selectif de la cyclooxygenase-2
ATE374753T1 (de) 2001-12-21 2007-10-15 Vernalis Cambridge Ltd 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
ES2335276T3 (es) 2002-03-13 2010-03-24 Array Biopharma, Inc. Derivados de bencimidazol alquilado n3 como inhibidores de mek.
CA2537991A1 (fr) 2003-09-23 2005-03-31 Novartis Ag Polytherapie combinant un inhibiteur des recepteurs du facteur vegf avec un agent chimiotherapeutique
DK1692113T3 (en) 2003-11-14 2018-01-08 Lorus Therapeutics Inc ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
EP1706400A1 (fr) 2004-01-09 2006-10-04 Novartis AG Derives de phenyl- 4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl¨-amine utilises comme inhibiteurs du recepteur igf-1r
ES2396135T3 (es) 2004-06-10 2013-02-19 Irm Llc Compuestos y composiciones como inhibidores de proteínas cinasas
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
MX2007011435A (es) 2005-03-17 2007-12-05 Novartis Ag N-[3-(1-amino-5,6,7,8-tetrahidro-2,4,4b-triazafluoren-9-il)-fenil ]-benzamidas como inhibidores de cinasa de tirosina/treonina, en particular de cinasa b-raf.
US20070099856A1 (en) 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
WO2007021966A1 (fr) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Composes pyrazoles modulant l'activite de la proteine hsp90
JP2009504796A (ja) 2005-08-22 2009-02-05 ノバルティス アクチエンゲゼルシャフト ｐＨ依存性薬剤化合物、ｐＨ調整剤および遅延剤を含む医薬組成物
JP2009506040A (ja) 2005-08-26 2009-02-12 スミスクライン・ビーチャム・コーポレイション オーロラキナーゼのピリミジニル−ピラゾール阻害剤
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
EP2024353A2 (fr) * 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazoles
MX2008012716A (es) 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
WO2007123892A2 (fr) * 2006-04-17 2007-11-01 Arqule Inc. Inhibiteurs raf et leurs utilisations
EP2061772A4 (fr) 2006-09-11 2011-06-29 Curis Inc Petites molécules multifonctionnelles servant d'agents anti-prolifératifs
ATE552835T1 (de) 2006-09-18 2012-04-15 Boehringer Ingelheim Int Verfahren zur behandlung von tumoren mit egfr- mutationen
US8202876B2 (en) 2006-10-02 2012-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2664147A1 (fr) * 2006-10-06 2008-04-17 Irm Llc Inhibiteurs de la proteine kinase et procedes pour utiliser ceux-ci
CA2677651A1 (fr) 2007-02-15 2008-08-21 Novartis Ag Combinaisons d'agents therapeutiques pour le traitement du cancer
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
WO2009016460A2 (fr) * 2007-08-01 2009-02-05 Pfizer Inc. Composés pyrazoles
WO2009050291A2 (fr) 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Produit de dispersion solide de médicaments de type n-aryle à base d'urée
CA2704436C (fr) * 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Derives imidazo[1,2-a]pyridine et leur utilisation comme modulateurs allosteriques positifs des recepteurs mglur2
JP5384611B2 (ja) 2008-03-21 2014-01-08 ノバルティス アーゲー 新規ヘテロ環式化合物およびそれらの使用
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN102105459B (zh) * 2008-07-24 2014-09-10 内尔维阿诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑类
JP2011529504A (ja) 2008-07-28 2011-12-08 ギリアード サイエンシーズ， インコーポレイテッド シクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物およびヘテロシクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物
PE20110294A1 (es) 2008-09-29 2011-05-26 Boehringer Ingelheim Int Compuestos heterociclicos como inhibidores de enzimas de senal especifica
ES2598178T5 (es) 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
WO2010056662A1 (fr) * 2008-11-11 2010-05-20 University Of Washington Signalisation de wnt-bêta-caténine dans le mélanome
JP5490137B2 (ja) * 2008-12-19 2014-05-14 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ プロテインキナーゼ阻害薬としての二環式ピラゾール
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru) 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (fr) 2009-03-04 2010-09-10 Novartis Ag Dérivés d'imidazole disubstitués en tant que modulateurs de la protéine kinase raf
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
JP5789602B2 (ja) * 2009-06-15 2015-10-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピリミジニルピロロピリジノン誘導体、これらの製造のための方法およびキナーゼ阻害剤としてのこれらの使用
KR101256018B1 (ko) * 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CA2786509C (fr) 2010-01-27 2016-01-05 Nerviano Medical Sciences S.R.L. Derives sulfonamido des 3,4-diarylpyrazones comme inhibiteurs des proteines kinases
RU2017144535A (ru) 2010-03-30 2019-02-18 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
JP5938038B2 (ja) 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用
KR101909313B1 (ko) 2011-03-21 2018-10-17 발큐리아 에이비 Hdac 저해제 및 스테로이드를 포함하는 약학적 조성물 및 이의 용도
PE20140604A1 (es) 2011-06-14 2014-05-13 Novartis Ag Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa
CA2855243C (fr) 2011-11-11 2020-04-14 Novartis Ag Procede de traitement d'une maladie proliferative
JP6216325B2 (ja) 2011-11-23 2017-10-18 ノバルティス アーゲー 医薬製剤
RU2015121367A (ru) 2012-11-08 2017-01-10 Новартис Аг Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний
US10576680B2 (en) 2015-11-19 2020-03-03 The Boeing Company Modular thermoforming system

Also Published As

Publication number Publication date
EA201500175A1 (ru) 2015-05-29
US20180297986A1 (en) 2018-10-18
UA112285C2 (uk) 2016-08-25
NL300973I2 (nl) 2022-05-05
US20180297985A1 (en) 2018-10-18
NO2019011I1 (no) 2019-03-05
TN2012000081A1 (en) 2013-09-19
CY2019013I1 (el) 2019-11-27
CA2771775A1 (fr) 2011-03-03
KR20120062839A (ko) 2012-06-14
DK2727918T3 (da) 2017-01-23
ZA201202020B (en) 2012-12-27
NL300973I1 (fr) 2019-03-27
AU2010286569C1 (en) 2019-11-28
JP5475888B2 (ja) 2014-04-16
JO3002B1 (ar) 2016-09-05
US20230116233A1 (en) 2023-04-13
CY2019014I1 (el) 2019-11-27
IN2012DN02469A (fr) 2015-08-21
PT2727918T (pt) 2017-01-20
HN2012000441A (es) 2015-01-05
USRE49556E1 (en) 2023-06-20
CU20120034A7 (es) 2012-06-21
JP2013503186A (ja) 2013-01-31
JP2014098022A (ja) 2014-05-29
US20160280687A1 (en) 2016-09-29
US9593099B2 (en) 2017-03-14
GEP20146102B (en) 2014-05-27
AU2010286569A1 (en) 2012-04-12
US8501758B2 (en) 2013-08-06
LUC00101I2 (fr) 2020-01-23
CY1118452T1 (el) 2017-07-12
ME01860B (me) 2014-12-20
LTPA2019005I1 (lt) 2019-03-25
LTPA2019006I1 (lt) 2019-03-25
ES2492499T3 (es) 2014-09-09
MY156259A (en) 2016-01-29
BR112012004453A8 (pt) 2021-06-08
CA2771775C (fr) 2015-01-20
DOP2012000051A (es) 2012-05-31
GT201200053A (es) 2014-03-27
LT2727918T (lt) 2017-01-25
NI201200029A (es) 2012-05-29
ME02684B (fr) 2017-06-20
BR112012004453B1 (pt) 2022-04-26
US10568884B2 (en) 2020-02-25
PE20120861A1 (es) 2012-07-14
EP2727918B1 (fr) 2016-10-12
MX2012002546A (es) 2012-04-11
SI2727918T1 (sl) 2017-02-28
US9314464B2 (en) 2016-04-19
US10576080B2 (en) 2020-03-03
ES2610825T3 (es) 2017-05-03
US20130296318A1 (en) 2013-11-07
US20160263113A1 (en) 2016-09-15
NZ598924A (en) 2013-07-26
US9850230B2 (en) 2017-12-26
AR077975A1 (es) 2011-10-05
NO2019012I1 (no) 2019-03-05
AU2010286569B2 (en) 2013-10-10
EA201200373A1 (ru) 2012-09-28
CN102725283A (zh) 2012-10-10
SMT201400133B (it) 2014-11-10
SG178351A1 (en) 2012-03-29
HUE032847T2 (hu) 2017-11-28
CY2019014I2 (el) 2019-11-27
RS55568B1 (sr) 2017-05-31
EA025222B1 (ru) 2016-12-30
IL218084A0 (en) 2012-04-30
JP6045519B2 (ja) 2016-12-14
US20200323852A1 (en) 2020-10-15
BR112012004453A2 (pt) 2021-03-09
CO6612222A2 (es) 2013-02-01
WO2011025927A1 (fr) 2011-03-03
HRP20170005T1 (hr) 2017-03-10
US9593100B2 (en) 2017-03-14
SG10201405311TA (en) 2014-09-26
CY2019013I2 (el) 2019-11-27
US10005761B2 (en) 2018-06-26
LUC00102I2 (fr) 2024-05-21
CN103896921A (zh) 2014-07-02
EP2727918A1 (fr) 2014-05-07
HUS1900013I1 (hu) 2019-04-29
LTC2470526I2 (lt) 2020-04-27
PT2470526E (pt) 2014-09-01
SI2470526T1 (sl) 2014-09-30
SMT201700036B (it) 2017-03-08
PL2470526T3 (pl) 2014-10-31
LUC00101I1 (fr) 2019-02-13
DK2470526T3 (da) 2014-08-25
CL2012000340A1 (es) 2012-08-17
CN102725283B (zh) 2014-02-26
CN103896921B (zh) 2016-02-24
US20160122324A1 (en) 2016-05-05
IL218084A (en) 2016-11-30
US20110306625A1 (en) 2011-12-15
HRP20140799T1 (hr) 2014-11-07
HK1167390A1 (en) 2012-11-30
RS53489B1 (en) 2015-02-27
US20160280686A1 (en) 2016-09-29
ECSP12011700A (es) 2012-03-30
UY32860A (es) 2011-03-31
ECSP23004573A (es) 2023-04-28
KR101413392B1 (ko) 2014-06-27
US9850229B2 (en) 2017-12-26
HUS1900012I1 (hu) 2019-04-29
US20160120866A1 (en) 2016-05-05
CU24110B1 (es) 2015-07-30
PL2727918T3 (pl) 2017-06-30
EP2470526B1 (fr) 2014-05-28
CR20120102A (es) 2012-05-02
EP2470526A1 (fr) 2012-07-04

Similar Documents

Publication Publication Date Title
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA34969B1 (fr) Composes et compositions en tant qu inibiteurs de trk
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA28435B1 (fr) Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA34474B1 (fr) Agonistes de gpr40
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
BRPI0409173A (pt) compostos e composições como inibidores de proteìna quinase
MA33593B1 (fr) Composés hétérocycliques et leurs utilisations
TW200612926A (en) Compounds and compositions as ppar modulators
MA41179A (fr) Composés inhibiteurs de parg
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA30339B1 (fr) Azolopyrimidines inhibitrices de l'activite du recepteur cannabinoïde 1
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
MA32804B1 (fr) Antagonistes d'isonicotinamide des récepteurs de l'orexine
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
MA31707B1 (fr) Dérivés de benzimidazole et d'indole substitués par de l'oxadiazole et oxazole comme inhibiteurs de dgat1
MA30798B1 (fr) Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1
MA33241B1 (fr) Composes pour le traitement de troubles metaboliques